United States Biobank Market Insight
Published: 15 June 2026 | Report Format: Electronic (PDF)
The United States Biobank Market is projected to grow at a CAGR of around 7.8%, driven by increasing adoption of precision medicine, rising genomic research activities, expanding clinical trial programs, and growing investments in biospecimen preservation infrastructure.
United States Biobank Market Forecasts to 2035
- The United States Biobank Market Size Was Estimated at USD 1.82 Billion in 2025.
- The Market Size is Expected to Grow at a CAGR of around 7.8% from 2025 to 2035.
- The United States Biobank Market Size is Expected to Reach around USD 3.86 Billion by 2035.
Notable Insights for the United States Biobank Market
- Segmentation Based on Specimen Type, blood products, tissue samples, and nucleic acid specimens held a dominant position in the United States Biobank Market in 2025 with nearly 72% share, supported by their extensive use in genomics and translational research.
- Segmentation Based on Application, therapeutic research, clinical research, and regenerative medicine segments collectively accounted for approximately 74% share in 2025, owing to increasing utilization of biobanked samples in drug development initiatives.
- The United States Biobank Market is led by Thermo Fisher Scientific Inc., Azenta Life Sciences, and BioIVT LLC, with combined revenues exceeding USD 46.48 Billion in 2025, highlighting strong commercial capabilities supporting biospecimen management and life sciences services.
- Growing integration of artificial intelligence, digital pathology platforms, and genomic databases is projected to improve biospecimen accessibility by approximately 27% and research efficiency by nearly 24% during the forecast period.
Download the eBook (ToC)
Why Buy This Report
- Provides a comprehensive analysis of the impact of precision medicine initiatives, genomic research expansion, clinical trial activities, and biobanking investments on market growth.
- Offers key insights into technological advancements in automated sample storage systems, digital biobank management platforms, and biospecimen tracking innovations.
- Helps stakeholders evaluate competitive positioning, operational strategies, product development initiatives, strategic collaborations, regulatory trends, and long-term growth opportunities across the biobanking value chain.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States biobank market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Biobank Market
-
- Thermo Fisher Scientific Inc.
- Azenta Life Sciences
- BioIVT LLC
- Precision for Medicine
- Brooks Automation, Inc.
- Labcorp Biopharma Laboratory Services
- Charles River Laboratories International, Inc.
- IQVIA Holdings Inc.
- Indivumed GmbH
- US Biolab Corporation
Recent Developments:
- In September 2025, Azenta Life Sciences launched an advanced automated biorepository storage platform integrating enhanced sample traceability and scalable cold-chain capabilities to support large-scale genomic research programs.
- In May 2025, BioIVT LLC collaborated with a leading U.S.-based pharmaceutical company to expand access to high-quality annotated biospecimens for precision medicine and biomarker discovery applications.
Market Segmentation:
United States Biobank Market, By Specimen Type
-
- · Blood Products
- · Tissue Samples
- · Nucleic Acids
- · Cell Lines
- · Biological Fluids
- · Others
United States Biobank Market, By Biobank Type
-
- · Population-Based Biobanks
- · Disease-Oriented Biobanks
- · Virtual Biobanks
- · Tissue Biobanks
United States Biobank Market, By Application
-
- · Therapeutic Research
- · Clinical Research
- · Regenerative Medicine
- · Drug Discovery
- · Biomarker Development
- · Others
United States Biobank Market, By Ownership
-
- · Government
- · Academic Institutions
- · Private Organizations
- · Non-Profit Organizations
United States Biobank Market, By End User
-
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Hospitals and Healthcare Organizations
- Contract Research Organizations
- Others
Expert Views:
The United States Biobank Market is anticipated to witness robust growth through 2035, supported by expanding precision medicine programs, increasing genomic sequencing initiatives, and rising demand for high-quality biospecimens. Continued investments in automation technologies, digital biobanking solutions, and collaborative research networks are expected to enhance sample accessibility, improve operational efficiency, and strengthen the market's long-term growth potential.